Fredun Pharmaceuticals logo

Fredun Pharmaceuticals

FREDUN NSE

Key Fundamentals

MicrocapPharmaceuticalsHealthcare
Market Cap
₹2,355 Cr
Volatility
Moderate
P/E Ratio
50.27
EBITDA
₹94.50 Cr
Return on Equity
11.73%
Debt to Equity
0.8
Book Value
₹162.78
52W High
₹1,590
52W Low
₹1,320.1

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

4
  • Company is expected to give good quarter
  • Company has delivered good profit growth of 75.2% CAGR over last 5 years
  • Debtor days have improved from 87.9 to 53.2 days.
  • Company's median sales growth is 28.6% of last 10 years

Weaknesses

2
  • Stock is trading at 8.31 times its book value
  • Promoter holding has decreased over last 3 years: -5.05%

Growth Rate

Revenue Growth
40.06% higher than 3Y
Net Income Growth
65.48% higher than 3Y
Cash Flow Change
172% lower than 3Y
ROE
-15.97%
ROCE
-20.13%
EBITDA Margin (Avg.)
22.94%

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
62
82
87
118
79
107
103
167
120
145
161
213
228
Expenses
54
72
76
107
68
93
89
150
103
123
135
184
195
Operating Profit
8
10
11
11
10
14
13
17
17
22
26
29
33
OPM %
12%
12%
12%
9%
13%
13%
13%
10%
14%
15%
16%
14%
14%
Other Income
0
0
0
0
0
0
0
0
0
0
0
0
0
Interest
3
3
4
4
4
5
5
8
7
8
11
14
9
Depreciation
1
1
1
1
1
1
1
1
1
2
2
3
4
PBT
4
6
6
6
6
8
7
8
9
13
14
12
21
Tax %
41%
32%
27%
13%
25%
44%
25%
12%
25%
25%
25%
4%
36%
Net Profit
2
4
4
5
4
4
5
7
7
10
10
11
13
EPS in Rs
1.75
2.79
2.99
3.59
2.91
3.01
3.75
4.98
4.77
6.85
6.51
6.75
7.98
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
25
42
57
60
97
113
134
222
275
348
454
635
748
Expenses
24
38
53
54
87
104
126
208
247
310
401
544
637
Operating Profit
2
4
3
6
10
8
8
14
28
38
53
91
111
OPM %
7%
9%
6%
10%
11%
7%
6%
6%
10%
11%
12%
14%
15%
Other Income
0
1
2
0
0
1
1
2
2
1
2
4
0
Interest
1
2
2
2
3
4
4
5
9
14
22
39
41
Depreciation
1
1
1
1
1
2
2
2
3
4
4
8
10
PBT
1
2
2
3
6
2
3
9
18
21
28
48
59
Tax %
52%
42%
36%
34%
28%
24%
37%
26%
38%
27%
26%
30%
—
Net Profit
0
1
1
2
4
2
2
6
11
16
21
33
44
EPS in Rs
0.37
1.51
2.01
1.7
3.72
1.58
1.68
4.77
7.95
11.08
14.65
20.25
28.09
Div. Payout %
0%
13%
10%
12%
6%
14%
14%
5%
3%
2%
2%
1%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
2
2
2
3
4
4
4
4
5
5
5
5
Reserves
0
1
2
19
35
37
39
64
92
117
137
273
Borrowings
9
16
21
10
19
35
40
53
87
106
166
222
Other Liabilities
11
24
30
47
47
65
79
66
74
81
179
141
Total Liabilities
23
43
56
79
105
141
162
187
257
308
487
642
Fixed Assets
8
15
16
16
31
31
30
32
39
47
53
118
CWIP
1
0
4
11
0
0
0
0
0
0
0
0
Investments
0
0
0
0
0
0
0
0
0
1
2
2
Other Assets
14
29
36
52
74
110
131
155
218
260
433
522
Total Assets
23
43
56
79
105
141
162
187
257
308
487
642
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
2
3
4
17
1
-11
0
-2
-14
0
-21
16
Investing
-3
-6
-7
-8
-5
-1
-1
-4
-9
-8
-6
-74
Financing
1
3
3
-8
4
14
-1
7
25
6
26
122
Net Cash Flow
0
1
-1
1
0
2
-2
1
1
-2
-1
65
Free Cash Flow
-1
-3
-3
9
-4
-12
-1
-7
-24
-8
-27
-57
CFO/OP
108
85
117
303
8
-128
2
-17
-52
-1
-43
18
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
75
98
131
94
67
126
112
148
46
68
142
53
Inventory Days
102
140
68
170
249
227
242
96
264
246
267
219
Days Payable
167
221
224
360
205
208
215
101
104
88
161
71
Cash Conversion Cycle
11
17
-24
-96
110
145
139
144
205
225
248
201
Working Capital Days
-54
-44
-39
42
66
65
116
126
97
92
76
79
ROCE %
14%
25%
18%
16%
21%
10%
10%
13%
18%
17%
19%
21%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Fredun Pharmaceuticals insights

62 extracted metrics + investor summaries across FY07–FY26.

Log in — free

Shareholding Pattern

FIIs1.06%Promot.44.57%DIIs2.94%Others7.65%Public43.79%As ofJun 2026

Documents

Frequently Asked Questions about Fredun Pharmaceuticals

What does Fredun Pharmaceuticals Ltd do?
Incorporated in 1987, Fredun Pharmaceuticals Ltd manufactures & exports healthcare and pharmaceuticals products[1]
Where is Fredun Pharmaceuticals Ltd (539730) listed?
Fredun Pharmaceuticals Ltd trades as FREDUN on the NSE and under code 539730 on the BSE.
Which sector does Fredun Pharmaceuticals Ltd belong to?
Fredun Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Fredun Pharmaceuticals Ltd?
Fredun Pharmaceuticals Ltd has a market capitalisation of ₹2,355 Cr, which places it in the Small Cap band.
What is the PE ratio of Fredun Pharmaceuticals Ltd?
Fredun Pharmaceuticals Ltd trades at a PE ratio of 50.27, against a book value of ₹162.78 per share.
What is the 52-week high and low of Fredun Pharmaceuticals Ltd?
Over the last 52 weeks Fredun Pharmaceuticals Ltd has traded between ₹1,320.1 and ₹1,590.
Does Fredun Pharmaceuticals Ltd pay dividends?
Fredun Pharmaceuticals Ltd has a dividend yield of 0.05%.
What is the Return on Equity (ROE) of Fredun Pharmaceuticals Ltd?
Fredun Pharmaceuticals Ltd reported a return on equity of 11.73%. Its debt-to-equity ratio is 0.80.

Company Information

Incorporated in 1987, Fredun Pharmaceuticals Ltd manufactures & exports healthcare and pharmaceuticals products[1]

Website fredungroup.com
Listed 2016-03-28
Face Value ₹ 10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/539730.md for Fredun Pharmaceuticals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List